
For-Robin Therapeutics, a US-based company, develops antibody immunotherapy for all breast cancer types, including triple negatives.
For-Robin Therapeutics, founded in Williamsville, United States, is dedicated to developing antibody immunotherapy for breast cancer treatment. Named in honor of the founder’s sister, Robin Quataert, who passed away from estrogen and progesterone receptor-negative breast cancer, the company’s mission is to provide effective treatments for all breast cancer subtypes, particularly triple-negative breast cancer. Their proprietary technology includes the monoclonal antibody JAA-F11 and its humanized variants, which target a broad spectrum of breast cancer cells.
Notable affiliations include partnerships with the National Cancer Institute's NExT program, supporting IND-enabling antibody production and safety studies. Key achievements involve advancing their proprietary antibodies towards clinical trials scheduled for 2023-24. For-Robin's impact lies in its potential to offer targeted therapy options for breast cancer patients, addressing a critical unmet need in oncology.
For-Robin's most recent funding round was for $2M (USD) in May 2015.
As of May 4, 2015, For-Robin has disclosed funding of $2M (USD).

Robin Care
SunnyBay BioTech

Grid Therapeutics

Etira
etira.life

Nascent Biotech
nascentbiotech.com

Qrono
qrono.com

Fortis Therapeutics

Ribon Therapeutics
ribontx.com

FLAG Therapeutics

ENB Therapeutics
enbpharma.com

Falcon Therapeutics

Rakuten Medical
rakuten-med.com

G1 Therapeutics
g1therapeutics.com

Resonant Therapeutics
resonantrx.com

CancerVAX
cancervax.com

OncoResponse

Northwest Biotherapeutics
nwbio.com

Rondo Therapeutics
rondotx.com

Tradewind BioScience
tradewindbio.com

Avotres
avotres.com